Research

Modulation of lung inflammation by vessel dilator in a mouse model of allergic asthma

Xiaoqin Wang^1,2 , Weidong Xu² , Xiaoyuan Kong² , Dongqing Chen² , Gary Hellermann² , Terry A Ahlert⁴ , Joseph D Giaimo⁴ , Stephania A Cormier⁴ , Xu Li¹ , Richard F Lockey^2,5 , Subhra Mohapatra^3,5 and Shyam S Mohapatra^2,5

¹  Clinical Laboratory Center of First Affiliated Hospital, Xi'an Jiaotong University College of Medicine, Xi'an, PR China

²  Division of Allergy and Immunology, University of South Florida, Tampa, FL 33612, USA

³  Division of Endocrinology, Department of Internal Medicine, University of South Florida, Tampa, FL 33612, USA

⁴  Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA

⁵  VA Hospital Medical Center, Tampa, FL 33612, USA

author email corresponding author email

Respiratory Research 2009, 10:66doi:10.1186/1465-9921-10-66

Published:	17 July 2009

Abstract

Background

Atrial natriuretic peptide (ANP) and its receptor, NPRA, have been extensively studied in terms of cardiovascular effects. We have found that the ANP-NPRA signaling pathway is also involved in airway allergic inflammation and asthma. ANP, a C-terminal peptide (amino acid 99–126) of pro-atrial natriuretic factor (proANF) and a recombinant peptide, NP73-102 (amino acid 73–102 of proANF) have been reported to induce bronchoprotective effects in a mouse model of allergic asthma. In this report, we evaluated the effects of vessel dilator (VD), another N-terminal natriuretic peptide covering amino acids 31–67 of proANF, on acute lung inflammation in a mouse model of allergic asthma.

Methods

A549 cells were transfected with pVD or the pVAX1 control plasmid and cells were collected 24 hrs after transfection to analyze the effect of VD on inactivation of the extracellular-signal regulated receptor kinase (ERK1/2) through western blot. Luciferase assay, western blot and RT-PCR were also performed to analyze the effect of VD on NPRA expression. For determination of VD's attenuation of lung inflammation, BALB/c mice were sensitized and challenged with ovalbumin and then treated intranasally with chitosan nanoparticles containing pVD. Parameters of airway inflammation, such as airway hyperreactivity, proinflammatory cytokine levels, eosinophil recruitment and lung histopathology were compared with control mice receiving nanoparticles containing pVAX1 control plasmid.

Results

pVD nanoparticles inactivated ERK1/2 and downregulated NPRA expression in vitro, and intranasal treatment with pVD nanoparticles protected mice from airway inflammation.

Conclusion

VD's modulation of airway inflammation may result from its inactivation of ERK1/2 and downregulation of NPRA expression. Chitosan nanoparticles containing pVD may be therapeutically effective in preventing allergic airway inflammation.